SRPK1 and cancer: Building on the experiences gained from our work with peptide drug conjugates, we were inspired by previous studies showing that targeting of SRPK1 results in enhanced sensitivity to platinum-based chemotherapy in some types of cancer.2,4 Two hybrid molecules, geo15 and geo140, were designed and synthesized which combine known SRPK1 inhibitors (SRPIN803, JH-VII-139-1) with the antimetabolites gemcitabine and 5-FU.